Protocol Single compound
Semax
ACTH(4-10) analog researched for neurotrophic (BDNF) and attention-related effects.
Compare side by side →Compared with:Semax vs Selank
Protocol card · research reference
- Starting dose
- 0.3 mg
- Studied range
- 0.3–0.9 mg
- Frequency
- 1–2× daily
- Route
- Subcutaneous or intranasal
- Cycle
- 2–4 weeks
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Semax
1–2× daily · units to draw on a U-100 syringe for a 0.3 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 | 6 u | 16 |
| 5 mg | 2 mL | 2.5 | 12 u | 16 |
| 5 mg | 3 mL | 1.67 | 18 u | 16 |
| 10 mg | 1 mL | 10 | 3 u | 33 |
| 10 mg | 2 mL | 5 | 6 u | 33 |
| 10 mg | 3 mL | 3.33 | 9 u | 33 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of the ACTH(4-10) fragment, with no hormonal activity on the adrenal glands. Rodent studies link it to higher brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus.
02
Observed research endpoints
- A single application raised BDNF and TrkB expression in the rat hippocampus.
- The same work tied these changes to improved learning in rats.
- Russian clinical studies have looked at it in ischemic stroke recovery.
03
Regulatory & safety context
- Registered as a medicine in Russia; not approved by the FDA or EMA.
- Most clinical literature is Russian-language and not independently replicated in large Western trials.
04
Citations
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60.2006Animal studyRead paper ↗
- Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61–68.2018Clinical study (Russian-language)Read paper ↗
Keep exploring
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon